AJMC October 30, 2019
As the number of high-cost orphan drugs and gene and cell therapies continues to grow, there will be a greater need for alternative payment models (APMs) to help figure out the best way to pay for these treatments.
During a session at AMCP Nexus 2019, panelists discussed how value-based contracts can affect different stakeholders, the value of these payment models, some challenges to implementing APMs, and some examples of success happening in the market.
There are really 4 stakeholders surrounding the patient, explained Roger Longman, MA, chairman, Real Endpoints. These stakeholders are:
- Payers, who want to simply pay for what works based on the demonstrated value;
- Manufacturers, who want to lower the barriers to their drugs and differentiate from...